Form 4: BioXcel Therapeutics CSO Executes RSU Vesting and Sale

Chief Scientific Officer Frank Yocca acquired 17,500 shares via RSU vesting and sold 6,845 shares to cover tax obligations.

Summary

• Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, Inc., reported the vesting of 17,500 Restricted Stock Units (RSUs) on May 4, 2026.
• Following the vesting, the reporting person sold 6,845 shares of common stock on May 20, 2026, at a weighted average price of $1.085 per share.
• The sale was conducted under a pre-established Rule 10b5-1 trading plan specifically to satisfy tax withholding requirements.
• Post-transaction, the reporting person maintains beneficial ownership of 26,175 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action related to tax obligations rather than a strategic divestment.

Positives

• The transaction was executed under a pre-planned Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than discretionary market timing.

Negatives

• The sale of shares, even for tax purposes, reduces the insider's direct equity stake in the company.

Risks

• Continued reliance on equity-based compensation and the potential for future tax-related sales to impact share liquidity.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Management Comments

• The reporting person confirmed the sale was effected solely to cover taxes due in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that routine insider sales for tax purposes following RSU vesting are standard corporate governance practices in the biotechnology sector and generally do not signal a change in management sentiment regarding company prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard industry practice for executives to manage equity compensation while avoiding potential conflicts of interest regarding material non-public information.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and limited to tax coverage.

Next Steps

• Continued monitoring of insider ownership levels in future SEC filings.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Insider Trading, Form 4, Restricted Stock Units, Rule 10b5-1